NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision
AMPLIFY tested acalabrutinib and venetoclax with and without obinutuzumab. NICE recommended the doublet, which is a decision about infusions.
HTA
NICE Said Yes to the Lung Machine, and Then Attached Four Years of Conditions
NICE conditionally recommended the XVIVO perfusion system for NHS use, with four years of evidence generation and a hub model to end the postcode divide.
Approval Is Day One. In Canada, Patients Wait Another Five Hundred Days.
A Canadian government task force counted the wait for public drug coverage: 200 days for HTA, 195 for price negotiation, then up to 219 more per province.
Italy Ran an Innovation Test for Eight Years.
Italy graded new medicines full, conditional or not innovative for eight years. The 2025 reform abolished the middle grade, because almost nothing ever graduated.
HAS Stroke Update Transforms Access on World Stroke Day
HAS strengthens stroke management for faster, equitable emergency care access.